Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer

摘要: OBJECTIVE: The aim of the present study was to assess patient compliance with tyrosine kinase inhibitor (TKI) treatment used for refractory and progressive thyroid cancer, in addition efficacy serious adverse events associated these agents. METHODS: We retrospectively analyzed data from adult patients metastatic differentiated or medullary cancer unresponsive conventional treated TKIs. Patients received until disease progression onset events, they expressed an intention stop treatment. RESULTS: Twenty-four median duration four (range: 1-19) cycles. most frequent were fatigue, nausea, diarrhea, hypertension, stomatitis, severe nasal bleeding, heart failure, rhabdomyolysis, renal QT prolongation, neutropenia, fatigue. Dose reduction required eight patients, while five decided terminate TKI therapy because impaired their everyday activities. During therapy, two showed a partial response three stable disease. lungs sites favoring treatment. CONCLUSION: Patient selection meticulous pretreatment education are necessary order ensure adherence therapy. If appear, dose temporary interruption may be offered some resolve continuation treatment. In event discontinuation is necessary.